Sudan Loganathan
Stock Analyst at Stephens
(3.50)
# 2,174
Out of 4,386 analysts
40
Total ratings
50%
Success rate
10.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics | Rated: Buy | $8 → $5 | $0.9777 | +411.40% | 3 | Jun 4, 2026 | |
| PVLA Palvella Therapeutics | Initiated Coverage: Buy | $220 | $105.25 | +109.03% | 1 | May 11, 2026 | |
| CPRX Catalyst Pharmaceuticals | Downgraded: Hold | $40 → $32 | $31.28 | +2.30% | 3 | May 7, 2026 | |
| CNTA Centessa Pharmaceuticals | Downgraded: Hold | $35 → $47 | $39.70 | +18.39% | 2 | Mar 31, 2026 | |
| IMNM Immunome | Rated: Buy | $33 → $30 | $18.61 | +61.20% | 3 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $110 → $100 | $73.95 | +35.23% | 3 | Mar 2, 2026 | |
| ARVN Arvinas | Maintained: Buy | $15 → $18 | $7.15 | +151.75% | 4 | Feb 25, 2026 | |
| APGE Apogee Therapeutics | Initiated Coverage: Buy | $95 | $83.01 | +14.44% | 1 | Dec 17, 2025 | |
| PYXS Pyxis Oncology | Maintained: Buy | $13 → $8 | $1.69 | +373.37% | 2 | Nov 24, 2025 | |
| CADL Candel Therapeutics | Initiated Coverage: Buy | $15 | $8.50 | +76.47% | 1 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $4 → $6 | $3.59 | +67.13% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $35 | $13.00 | +169.23% | 2 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $29 → $60 | $51.74 | +15.96% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $30 | $15.64 | n/a | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $5 | $1.06 | n/a | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20.92 | $12.44 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $31.48 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $25 | $4.11 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $10.94 | n/a | 1 | May 13, 2024 |
ADC Therapeutics
Jun 4, 2026
Rated: Buy
Price Target: $8 → $5
Current: $0.9777
Upside: +411.40%
Palvella Therapeutics
May 11, 2026
Initiated Coverage: Buy
Price Target: $220
Current: $105.25
Upside: +109.03%
Catalyst Pharmaceuticals
May 7, 2026
Downgraded: Hold
Price Target: $40 → $32
Current: $31.28
Upside: +2.30%
Centessa Pharmaceuticals
Mar 31, 2026
Downgraded: Hold
Price Target: $35 → $47
Current: $39.70
Upside: +18.39%
Immunome
Mar 4, 2026
Rated: Buy
Price Target: $33 → $30
Current: $18.61
Upside: +61.20%
Kymera Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: $110 → $100
Current: $73.95
Upside: +35.23%
Arvinas
Feb 25, 2026
Maintained: Buy
Price Target: $15 → $18
Current: $7.15
Upside: +151.75%
Apogee Therapeutics
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $95
Current: $83.01
Upside: +14.44%
Pyxis Oncology
Nov 24, 2025
Maintained: Buy
Price Target: $13 → $8
Current: $1.69
Upside: +373.37%
Candel Therapeutics
Oct 28, 2025
Initiated Coverage: Buy
Price Target: $15
Current: $8.50
Upside: +76.47%
Sep 15, 2025
Upgraded: Buy
Price Target: $4 → $6
Current: $3.59
Upside: +67.13%
Jun 30, 2025
Maintained: Buy
Price Target: $5 → $35
Current: $13.00
Upside: +169.23%
Jun 24, 2025
Upgraded: Buy
Price Target: $29 → $60
Current: $51.74
Upside: +15.96%
Apr 9, 2025
Maintained: Buy
Price Target: $20 → $30
Current: $15.64
Upside: n/a
Nov 19, 2024
Reiterated: Buy
Price Target: $25 → $5
Current: $1.06
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $20.92
Current: $12.44
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $31.48
Upside: n/a
Nov 7, 2024
Initiated Coverage: Hold
Price Target: $25
Current: $4.11
Upside: n/a
May 13, 2024
Rated: Buy
Price Target: $25
Current: $10.94
Upside: n/a